ALK inhibitors: plateauing systemic and intracranial activity?

The Lancet Oncology

Volumn 17, Issue 4, 2016, Pages 404-406

  Costa, Daniel B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 AMINO 5 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] N [4 (4 METHYL 1 PIPERAZINYLCARBONYL)PHENYL] 3 PYRIDAZINECARBOXAMIDE; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; BRIGATINIB; CERITINIB; CRIZOTINIB; DOCETAXEL; LORLATINIB; PEMETREXED; PLATINUM; PLATINUM COMPLEX; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; DRUG POTENCY; DRUG RESPONSE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG ADENOCARCINOMA; MONOTHERAPY; NON SMALL CELL LUNG CANCER; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; LUNG TUMOR;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84960154126     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)00025-5     Document Type: Note

References (10)

1. 1 Kwak, EL, Bang, YJ, Camidge, DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363 (2010), 1693–1703.
2. 2 Shaw, AT, Ou, SH, Bang, YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371 (2014), 1963–1971.
3. 3 Jorge, SE, Schulman, S, Freed, JA, et al. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer 90 (2015), 369–374.
4. 4 Shaw, AT, Kim, DW, Nakagawa, K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368 (2013), 2385–2394.
5. 5 Solomon, BJ, Mok, T, Kim, DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371 (2014), 2167–2177.
6. 6 Costa, DB, Shaw, AT, Ou, SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33 (2015), 1881–1888.
7. 7 Ou, SI, Ahn, JS, De Petris, L, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 34 (2016), 661–668.
8. 8 Shaw, AT, Gandhi, L, Gadgeel, SM, et al., on behalf of the study investigators. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 17 (2016), 234–242.
9. 9 Shaw, AT, Kim, DW, Mehra, R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370 (2014), 1189–1197.
10. 10 Kim, D-W, Mehra, R, Tan, DSW, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol, 2016 published online March 10. http://dx.doi.org/10.1016/S1470-2045(15)00614-2.